CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)	$ (6,770,215)	$ 2,343,982
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities
(Gain) Loss on change in derivative liability	1,043,515	(2,208,683)
Loss on conversion of Preferred Stock	5,088,524	0
Amortization of debt discount recorded as interest expense	0	36,309
Purchase warrant stock compensation expense	399,260	0
Changes in Assets and Liabilities:
Prepaid expenses	6,575	(1,176)
Accounts payable	(40,784)	(2,395)
Other payable	(1,851)	24,648
Accrued expenses and interest on notes payable	14,271	0
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES - CONTINUING OPERATIONS	(260,705)	192,685
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES - DISCONTINUED OPERATIONS	167,515	(199,227)
NET CASH (USED IN) PROVIDED BY OPERATIONS	(93,190)	(6,542)
CASH FLOWS FROM INVESTING ACTIVITIES - CONTINUING OPERATIONS
Investment in StemVax, LLC	5	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed asset - discontinued operations	0	(2,284)
NET CASH USED IN INVESTING ACTIVITIES - DISCONTINUED OPERATIONS	0	(2,284)
CASH FLOWS FROM FINANCING ACTIVITIES:
Due to related party	68,312	0
Payments on related party promissory notes	(7,200)	(24,300)
Proceeds from related party loan payable	24,287	0
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	85,399	(24,300)
NET INCREASE (DECREASE) IN CASH	(7,786)	(33,126)
CASH, BEGINNING OF PERIOD	7,964	41,090
CASH, END OF PERIOD	178	7,964
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	6,955	10,099
Taxes paid	0	0
SUPPLEMENTAL DISCLOSURES OF NON-CASH TRANSACTIONS
Issuance of common stock upon conversion of debt and accrued interest	0	57,750
Accrued interest capitalized into convertible note	4,607	23,184
Preferred stock exchange	$ 50	$ 0